Skip to main content
. Author manuscript; available in PMC: 2015 Apr 27.
Published in final edited form as: J Natl Cancer Inst. 2008 May 27;100(11):784–795. doi: 10.1093/jnci/djn157

Figure 6.

Figure 6

Immunohistochemistry of p16. A) Melanoma cell lines tested for p16 expression. In SK-MEL 94 and 147, expression is mostly cytoplasmic, with some nuclei showing reactivity. SK-MEL 173 is negative. Each panel is shown at ×200 magnification. B) Expression of p16 in melanoma tumor samples. Alterations to the p16 and ARF loci are listed for each tumor. HD = homozygous deletion; Hemi = hemizygous; Meth = promoter methylation; Hemi–Meth = hemizygous and promoter methylation; WT = wild type. Expression is seen in tumors in which either no alteration to the locus was observed (tumors 4 and 31) or only one alteration was observed (tumor 13). No expression was seen in tumor 34, in which two alterations to the locus were observed (hemizygous loss and promoter methylation). The ARF locus sustained two alterations in tumors 4, 13, and 31, which were positive for p16 expression.